Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NCT01497899Phase 2Completed
A Phase 2 trial of tenofovir alafenamide in human immunodeficiency virus type 1 infection (HIV-1), sponsored by Gilead Sciences. Started Dec 2011; status: completed.
Beyond the preview
Study design, results and competitive context are available in the Gosset platform where reported.
Available in the Gosset platform where reported.
Available in the Gosset platform where reported.
See how Gosset can support your research on NCT01497899.